(Q26739999)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

review article

3 references

26 January 2021

30 January 2021

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

complications of diabetes mellitus

20 March 2020

main subject

8 references

14 March 2019

24 March 2019

31 July 2019

2 October 2019

17 November 2019

15 December 2019

26 January 2021

30 January 2021

cell surface receptor

1 reference

31 July 2019

1 reference

2 October 2019

1 reference

17 November 2019

1 reference

15 December 2019

1 reference

26 January 2021

dipeptidyl peptidase-4 inhibitors

1 reference

30 January 2021

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Daiji Kawanami

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Keiichiro Matoba

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Kazunori Utsunomiya

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

29 July 2016

9 references

14 March 2019

24 March 2019

31 July 2019

2 October 2019

17 November 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

26 January 2021

30 January 2021

International Journal of Molecular Sciences

9 references

14 March 2019

24 March 2019

31 July 2019

2 October 2019

17 November 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

26 January 2021

30 January 2021

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

20 March 2020

copyright license

8 references

14 March 2019

24 March 2019

31 July 2019

2 October 2019

17 November 2019

15 December 2019

26 January 2021

30 January 2021

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Protective Effect of a GLP-1 Analog on Ischemia-Reperfusion Induced Blood-Retinal Barrier Breakdown and Inflammation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Signaling pathways in diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

28 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

28 September 2017

https://api.crossref.org/works/10.3390%2FIJMS17081223

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Dipeptidyl peptidase-4 inhibitors in progressive kidney disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

GIP and GLP-1, the two incretin hormones: Similarities and differences

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Regulation of claudins in blood-tissue barriers under physiological and pathological states

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Renal dopamine receptors, oxidative stress, and hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

What do we know about the secretion and degradation of incretin hormones?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Sensory nerve innervation of epineurial arterioles of the sciatic nerve containing calcitonin gene-related peptide: effect of streptozotocin-induced diabetes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

The pathogenesis of diabetic retinopathy: old concepts and new questions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Efficacy of glucagon-like peptide-1 mimetics for neural regeneration.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5000621

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

31 May 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Reduced Incretin Effect in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Beneficial Effects of PKF275-055, a Novel, Selective, Orally Bioavailable, Long-Acting Dipeptidyl Peptidase IV Inhibitor in Streptozotocin-Induced Diabetic Peripheral Neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17081223

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells

21 January 2018

1 reference

12 December 2020

Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin

1 reference

12 December 2020

Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV

1 reference

12 December 2020

Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats

1 reference

12 December 2020

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential

1 reference

12 December 2020

Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic

1 reference

12 December 2020

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

12 December 2020

Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model

1 reference

12 December 2020

Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

1 reference

12 December 2020

The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy

1 reference

12 December 2020

Dipeptidyl peptidase-IV inhibition prevents blood–retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats

1 reference

12 December 2020

Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level

1 reference

12 December 2020

GLP-1 agonist treatment: implications for diabetic retinopathy screening

1 reference

12 December 2020

Identifiers

DOI

10.3390/IJMS17081223

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27483245%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

2 references